Diverse in our backgrounds, training, and thinking
United in our mission

Taylor joined Engine in 2018 and has nearly fifteen years of experience in preclinical drug discovery and development, in the therapeutic areas of oncology, pain, inflammation and GI/liver therapeutics. She is an accomplished project leader of multiple drug discovery teams and has led strategic evaluations of pipeline programs. She brings many years of leadership in the development of biological assays.

Prior to joining Engine, Taylor was Director of Research Biology at Relypsa where she led the cross-functional team that prioritized the research pipeline for Relypsa’s gut-restricted polymer platform. She was the lead of the project team that developed multiple candidate ammonia binding polymers directed towards the treatment of Hepatic Encephalopathy. As the functional leader of the research biology group, she was also responsible for in vitro and in vivo biology support for Relypsa’s programs in research and development. Previously, Taylor was a Senior Scientist in Research Biology at Nektar Therapeutics, where she led several discovery stage projects including a discovery oncology program that identified multiple novel applications for polymer modified oncology drugs.

She earned her B.S. in Chemistry (cum laude) at Rensselaer Polytechnic Institute and Ph.D. in Biochemistry, Molecular and Cellular Biology from Cornell University, and she performed her postdoctoral studies at the University of California at Berkeley.

Amy is a managing partner of Polaris Partners in the New York office and focuses on investments in healthcare companies.

She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also represents Polaris as a director of Kallyope, Volastra, Thirty Madison and ByHeart. Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also manages the Polaris Innovation Fund which was formed in 2017.
Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after, Schulman became the president of Pfizer Consumer Healthcare.

Schulman has received numerous awards including 2019 PharmaVoice 100, Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Mount Sinai Hospital. She is also a member of Singapore’s Health and Biomedical Sciences International Advisory Council.

She is a Phi Beta Kappa graduate of Wesleyan University with a joint degree in philosophy and english and earned her J.D. from Yale Law School.

Hu is an Associate Professor at the Mayo Clinic. His group is focused on systems pharmacology and individualized systems medicine. Li’s team is active in developing novel network tools and harnessing machine learning methods to study context-dependent activities of regulatory networks at genome-wide scale. The major theme in the research team is to develop novel computational methods that can detect meaningful biological information embedded in the sea of Big Data and uncover novel regulatory mechanisms that explain the properties of biological phenotypes to benefit individualized disease diagnosis, drug discovery, and precision medicine. The developed computational platforms can greatly illuminate the understanding of disease mechanisms underlying drugs’ modes of action, addressing key challenges in Big Data-oriented biomedical complex systems and will ultimately lead to precision medicine for each patient suffering from a devastating disease.
​​
Hu completed his post-doctoral fellowship in systems biology at the Wyss Institute at Harvard Medical School and received his Ph.D. in computational biology and bioinformatics from the National University of Singapore.